[SINGAPORE] International biotech venture capital (VC) firms are flocking to Singapore, drawn by the Asia-Pacific region’s growing life sciences sector, with one more European VC confirmed to set up operations before year-end. This represents a significant change from a decade ago, when there were “practically zero VCs” of foreign origin in the biotech sector, noted Fabio La Mola, partner at consultancy firm Bain & Company. Over the past two years, several global players have established operations in the city-state. US-based VC firms Polaris Partners, Flagship Pioneering, Accelerator Life Science Partners and MPM BioImpact have all opened Singapore offices, alongside Novo Holdings, the investment arm of Danish diabetes drug manufacturer Novo Nordisk. Aside from VC, another important part of the early-stage ecosystem is the support from incubator networks during this same period. JLabs by American pharmaceutical giant Johnson & Johnson (J&J) and 65Lab backed by German drug discovery platform Evotec have also set up shop here.   https://www.businesstimes.com.sg/singapore/singapore-draws-international-biotech-vcs-asia-pacific-life-sciences-sector-takes? (ICE SINGAPORE)

Fonte notizia: The Business Times, 5 October 2025